OverweightNCT02351297
Effects of High Protein Diet on the Large Intestine in Overweight Humans
A study testing casein supplementation, soy protein supplementation and maltodextrin supplementation in people with Overweight and Healthy, run by Hospital Avicenne.
Trial summary
This study aims at evaluating the consequences of a 3 weeks high protein diet on the large intestine ecosystem (microbiota, metabolites and gene expression in rectal mucosa). Those parameters will be analysed with technics including OMICs methods. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Overweight, Healthy
- What is being tested?
- casein supplementation, soy protein supplementation and maltodextrin supplementation
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 42 participants
- Where
- No sites listed yet
- Study dates
- Jan 2015to May 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- BMI 25- 30
- Body weight stable last 3 months
- Moderate physical activity
Who cannot join
- Abnormal food behavior
- Digestive, renal, hepatic, pulmonary, hemostasis, neoplasic diseases
- antibiotic, pre or probiotics use in the last 3 months
- intolerance for the tested product
- positive serology for infectious disease
- pregnancy
About this study
This study aims at evaluating the consequences of a 3 weeks high protein diet on the large intestine ecosystem (microbiota, metabolites and gene expression in rectal mucosa). Those parameters will be analysed with technics including OMICs methods. After a run-in period, 42 volunteers will receive either soy or milk protein or maltodextrin as a placebo control. This trial is double blind randomized placebo-controlled paralleled design (3 arms). Longitudinal sampling will allow the comparison of parameters during the study.
Read the detailed description
High protein diets are widely used for their slimming effect. Those diets increase the quantity of undigested protein and peptides reaching the large intestine. Microbiota utilizes protein and peptides as substrates and produces amino-acid derived metabolites such as short chain fatty acids, branched chain fatty acids, lactate, formate, succinate, ammonium, hydrogen sulfide and phenolic compounds. Some of those metabolites have been shown to be beneficial to the host whereas other could be deleterious. High protein diets may have different effects whether based on animal or plant proteins since those two kinds of protein have different amino acids composition and slightly different digestibility. The objective of this study is to evaluate in overweight volunteers the consequences of high protein diets (animal vs vegetal) vs isocaloric-normoproteic diet at the level of the large intestine and metabolism. Firstly, composition and activity of the microbiota and the metabolites produced in the large intestine lumen will be determined. Then, to evaluate the consequences of the tested diets on mucosal physiology, gene expression will be analyzed in rectal biopsies and fecal water will be tested on colonocytes cell lines. Lastly, the consequences of the diets on host metabolism will be evaluated.
Dietary intervention
Before the study, volunteers (n=42) will provide a 3 day food record that will be utilized by a dietician to calculate their usual energy intake. The study will start with a 2 weeks normalization period during which the volunteers will have to eat according to menus (Fig. 1). The diet will provide to the volunteer their usual individual energy intake; and protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy intake.
At the end of this standardization period, volunteers will be randomly assigned into 3 groups (n=14) for 3 weeks (intervention period) (Fig. 1). Volunteers of the 3 groups will follow a diet with a reduced digestible carbohydrates intake (15% of energy intake) while undigestible carbohydrate intake will remain unchanged. The volunteers will consume 3 times per day a dietary supplement powder that they will dissolve in water and then drink. This supplement will provide them 15% of their energy intake. The first group will receive a casein (animal protein) supplement so that they will have a high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The second group will receive a soy protein(vegetal) supplement so that they will also consume a high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The third group will receive a maltodextrin (digestible carbohydrate, placebo control) supplement so that they will ingest a normoproteic diet, similar in macronutrient composition to the standardization diet (protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy intake). The dietary supplement will be given in a double-blinded protocol. There will be no energy restriction between the standaridization and intervention periods.
Clinical protocol
Daily, the volunteers will measure their body weight and record their food consumption and physical activity. Once a week, they will have a phone call with a dietician to ensure dietary compliance (Fig. 2).
At the end of the normalization period, 13 days after the beginning of the study (D13), volunteers will collect 24h urine samples. Stool samples will be collected from the evening of D13 to the morning of D14 . A cooler will be provided to the volunteer for storage and transport of samples. After one night fasting, in the morning of D14, the volunteers will come to the hospital and will bring their samples that will be immediately conditioned for storage. Blood samples will be collected. Then, rectal biopsies will be recovered. Every week during the intervention period, urine stool and blood will be sampled (D21, D28, D35). At the end of the intervention period, rectal biopsies will be recovered (D35). Body weight and blood pressure will be measured at each visit.
Analyses All measured parameters will be expressed relatively to baseline.
Dietary intake will be evaluated by dietician based on food records.
Stool samples
- Microbiota composition and functions
- Luminal metabolites composition
- pH, osmolarity, water content
- Fecal water test on HT-29 cells (colonocytes) for mitochondrial respiration, proliferation, genotoxicity, cytotoxicity, gene expression
Urines
- Urea and creatinine assay (protein consumption marker to verify dietary compliance)
- Metabolomics
Blood
- Clinical parameters (total cholesterol, LDL and HDL cholesterol, non-esterified fatty acids, triglycerides, glycemia, insulinemia)
- Metabolomics
Rectal biopsies
- Transcriptomic analyses
- Conditions
- Overweight, Healthy
- Being tested
- casein supplementation, soy protein supplementation, maltodextrin supplementation
- Keywords
- High protein diet, Microbiota, Rectal biopsies, Metabolomics, Bacterial metabolites, volunteers
- Medical subject headings
- Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
casein supplementationDietary supplement
After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
soy protein supplementationDietary supplement
After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
maltodextrin supplementationDietary supplement
After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Casein supplementation | Experimental | After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks. Receives: Dietary Supplement: casein supplementation |
| Soy protein supplementation | Experimental | After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks. Receives: Dietary Supplement: soy protein supplementation |
| Maltrodextrin supplementation | Placebo comparator | After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks. Receives: Dietary Supplement: maltodextrin supplementation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in gene expression in rectal biopsy from baseline after 3 week dietary intervention
Gene expression in biopsies collected before (baseline) and after 3 week dietary intervention will be measured by transcriptomic analyses. Differential gene expression will be expressed as relative units (fold change).
Measured: Change for baseline in gene expression in rectal biopsy after 3 weeks dietary intervention
Secondary outcomes (2)
microbiota composition analysis
Microbiota composition will be analysed in stool samples before (baseline) and after 3 week dietary intervention using metagenomic analyses and will be expressed as bacterial relative abundance.
Measured: Change for baseline in microbiota composition after 3 weeks dietary intervention
fecal water metabolomics
Fecal water metabolites will be analysed in stool samples before (baseline) and after 3 week dietary intervention using RMN analyses and will be expressed as metabolites relative abundance.
Measured: Change for baseline in fecal water metabolites after 3 weeks dietary intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2015 (estimated)
- Study startJan 2015
- Primary completionMay 2015
- Study completionMay 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital Avicenne
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Robert Benamouzig, Hospital Avicenne
- Investigators
- Robert BENAMOUZIG, MD PhD, Principal investigator, Avicenne Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02351297
- Sponsor's protocol ID
- 2013-A01730-45
- Status last verified
- Jan 2016
- First submitted
- 20 Jan 2015
- Last updated
- 21 Jan 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
Beaumont M, Portune KJ, Steuer N, Lan A, Cerrudo V, Audebert M, Dumont F, Mancano G, Khodorova N, Andriamihaja M, Airinei G, Tome D, Benamouzig R, Davila AM, Claus SP, Sanz Y, Blachier F. Quantity and source of dietary protein influence metabolite production by gut microbiota and rectal mucosa gene expression: a randomized, parallel, double-blind trial in overweight humans. Am J Clin Nutr. 2017 Oct;106(4):1005-1019. doi: 10.3945/ajcn.117.158816. Epub 2017 Sep 13.
PubMed 28903954
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of High Protein Diet on the Large Intestine in Overweight Humans
- ClinicalTrials.gov ID
- NCT02351297
- Acronym / sponsor ID
- 2013-A01730-45
- Conditions
- Overweight, Healthy
- Keywords
- High protein diet, Microbiota, Rectal biopsies, Metabolomics, Bacterial metabolites, volunteers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Hospital AvicenneUniversity, hospital or other
- Study start
- Jan 2015
- Primary completion
- May 2015 (actual)
- Study completion
- May 2015 (actual)
- First posted
- 30 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims at evaluating the consequences of a 3 weeks high protein diet on the large intestine ecosystem (microbiota, metabolites and gene expression in rectal mucosa). Those parameters will be analysed with technics including OMICs methods. After a run-in period, 42 volunteers will receive either soy or milk protein or maltodextrin as a placebo control. This trial is double blind randomized placebo-controlled paralleled design (3 arms). Longitudinal sampling will allow the comparison of parameters during the study.
Detailed description
High protein diets are widely used for their slimming effect. Those diets increase the quantity of undigested protein and peptides reaching the large intestine. Microbiota utilizes protein and peptides as substrates and produces amino-acid derived metabolites such as short chain fatty acids, branched chain fatty acids, lactate, formate, succinate, ammonium, hydrogen sulfide and phenolic compounds. Some of those metabolites have been shown to be beneficial to the host whereas other could be deleterious. High protein diets may have different effects whether based on animal or plant proteins since those two kinds of protein have different amino acids composition and slightly different digestibility. The objective of this study is to evaluate in overweight volunteers the consequences of high protein diets (animal vs vegetal) vs isocaloric-normoproteic diet at the level of the large intestine and metabolism. Firstly, composition and activity of the microbiota and the metabolites produced in the large intestine lumen will be determined. Then, to evaluate the consequences of the tested diets on mucosal physiology, gene expression will be analyzed in rectal biopsies and fecal water will be tested on colonocytes cell lines. Lastly, the consequences of the diets on host metabolism will be evaluated.
Dietary intervention
Before the study, volunteers (n=42) will provide a 3 day food record that will be utilized by a dietician to calculate their usual energy intake. The study will start with a 2 weeks normalization period during which the volunteers will have to eat according to menus (Fig. 1). The diet will provide to the volunteer their usual individual energy intake; and protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy intake.
At the end of this standardization period, volunteers will be randomly assigned into 3 groups (n=14) for 3 weeks (intervention period) (Fig. 1). Volunteers of the 3 groups will follow a diet with a reduced digestible carbohydrates intake (15% of energy intake) while undigestible carbohydrate intake will remain unchanged. The volunteers will consume 3 times per day a dietary supplement powder that they will dissolve in water and then drink. This supplement will provide them 15% of their energy intake. The first group will receive a casein (animal protein) supplement so that they will have a high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The second group will receive a soy protein(vegetal) supplement so that they will also consume a high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The third group will receive a maltodextrin (digestible carbohydrate, placebo control) supplement so that they will ingest a normoproteic diet, similar in macronutrient composition to the standardization diet (protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy intake). The dietary supplement will be given in a double-blinded protocol. There will be no energy restriction between the standaridization and intervention periods.
Clinical protocol
Daily, the volunteers will measure their body weight and record their food consumption and physical activity. Once a week, they will have a phone call with a dietician to ensure dietary compliance (Fig. 2).
At the end of the normalization period, 13 days after the beginning of the study (D13), volunteers will collect 24h urine samples. Stool samples will be collected from the evening of D13 to the morning of D14 . A cooler will be provided to the volunteer for storage and transport of samples. After one night fasting, in the morning of D14, the volunteers will come to the hospital and will bring their samples that will be immediately conditioned for storage. Blood samples will be collected. Then, rectal biopsies will be recovered. Every week during the intervention period, urine stool and blood will be sampled (D21, D28, D35). At the end of the intervention period, rectal biopsies will be recovered (D35). Body weight and blood pressure will be measured at each visit.
Analyses All measured parameters will be expressed relatively to baseline.
Dietary intake will be evaluated by dietician based on food records.
Stool samples
- Microbiota composition and functions
- Luminal metabolites composition
- pH, osmolarity, water content
- Fecal water test on HT-29 cells (colonocytes) for mitochondrial respiration, proliferation, genotoxicity, cytotoxicity, gene expression
Urines
- Urea and creatinine assay (protein consumption marker to verify dietary compliance)
- Metabolomics
Blood
- Clinical parameters (total cholesterol, LDL and HDL cholesterol, non-esterified fatty acids, triglycerides, glycemia, insulinemia)
- Metabolomics
Rectal biopsies
- Transcriptomic analyses
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Casein supplementation | Experimental | Dietary Supplement: casein supplementationAfter the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks. |
| Soy protein supplementation | Experimental | Dietary Supplement: soy protein supplementationAfter the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks. |
| Maltrodextrin supplementation | Placebo comparator | Dietary Supplement: maltodextrin supplementationAfter the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- BMI 25- 30
- Body weight stable last 3 months
- Moderate physical activity
Key exclusion criteria (6 listed)
- Abnormal food behavior
- Digestive, renal, hepatic, pulmonary, hemostasis, neoplasic diseases
- antibiotic, pre or probiotics use in the last 3 months
- intolerance for the tested product
- positive serology for infectious disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| casein supplementationAfter the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks. | Dietary supplement | Casein supplementation |
| soy protein supplementationAfter the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks. | Dietary supplement | Soy protein supplementation |
| maltodextrin supplementationAfter the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks. | Dietary supplement | Maltrodextrin supplementation |
Primary outcome
Change in gene expression in rectal biopsy from baseline after 3 week dietary intervention
Time frame: Change for baseline in gene expression in rectal biopsy after 3 weeks dietary intervention
Gene expression in biopsies collected before (baseline) and after 3 week dietary intervention will be measured by transcriptomic analyses. Differential gene expression will be expressed as relative units (fold change).
2 secondary outcomes
microbiota composition analysis
Time frame: Change for baseline in microbiota composition after 3 weeks dietary intervention
fecal water metabolomics
Time frame: Change for baseline in fecal water metabolites after 3 weeks dietary intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2016.
- Derived from this study: PubMed 28903954Beaumont M, Portune KJ, Steuer N, Lan A, Cerrudo V, Audebert M, Dumont F, Mancano G, Khodorova N, Andriamihaja M, Airinei G, Tome D, Benamouzig R, Davila AM, Claus SP, Sanz Y, Blachier F. Quantity and source of dietary protein influence metabolite production by gut microbiota and rectal mucosa gene expression: a randomized, parallel, double-blind trial in overweight humans. Am J Clin Nutr. 2017 Oct;106(4):1005-1019. doi: 10.3945/ajcn.117.158816. Epub 2017 Sep 13.
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert BENAMOUZIG, MD PhD principal investigator
Avicenne Hospital
Questions about this trial
What is this clinical trial studying?
A study testing casein supplementation, soy protein supplementation and maltodextrin supplementation in people with Overweight and Healthy, run by Hospital Avicenne.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in gene expression in rectal biopsy from baseline after 3 week dietary intervention (time frame: Change for baseline in gene expression in rectal biopsy after 3 weeks dietary intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02351297, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2016.